Vaxil Completes Oversubscribed Financing to Advance Its Cancer Immunotherapy Research and Development
Juggernaut Announces Strategic Investment by Crescat Capital Funds for 28.95% Ownership - Dr. Quinton Hennigh Technical Advisor